ATENOLOL LACTATION STUDY

阿替洛尔哺乳期研究

• 批准号: 7379364
• 负责人: MARY F HEBERT
• 金额: $ 3.8万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379364
• 关键词: ATENOLOL; LACTATION; STUDY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. High blood pressure is a common condition in pregnant women. Atenolol is an effective agent for the management of high blood pressure during and after pregnancy. We recently completed a study evaluating the pharmacokinetics of atenolol in pregnancy. However, no one has studied the pharmacokinetics of atenolol postpartum. Product labeling for atenolol states that "Atenolol is excreted in human breast milk at a ratio of 1.5 to 6.8 when compared to the concentration in plasma. Caution should be exercised when atenolol is administered to a nursing woman. Clinically significant bradycardia has been reported in breast fed infants. Premature infants, or infants with impaired renal function, may be more likely to develop adverse effects." Despite this warning, many women receiving atenolol for hypertension decide to breastfeed their infants. Because of the multiple health benefits for infants, exclusive breastfeeding for the first 6 months of life is recommended by the American Academy of Pediatrics and the World Health Organization. This study is designed to evaluate the pharmacokinetics of atenolol in plasma, urine and breast milk 2-4 weeks, 3-4 months and 6-8 months postpartum in women taking atenolol for therapeutic reasons and nursing their infants.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。高血压是孕妇的常见病。阿替洛尔是一种有效的治疗妊娠期间和妊娠后高血压的药物。我们最近完成了一项评估阿替洛尔在妊娠期药代动力学的研究。然而，没有人研究阿替洛尔产后的药代动力学。阿替洛尔的产品标签上写着“阿替洛尔在人类母乳中的排泄比例为1.5比6.8，与血浆中的浓度相比。哺乳期妇女服用阿替洛尔时应谨慎。在母乳喂养的婴儿中有临床意义的心动过缓的报道。早产儿或肾功能受损的婴儿更容易出现不良反应。”尽管有这样的警告，许多接受阿替洛尔治疗高血压的妇女还是决定母乳喂养婴儿。由于对婴儿的多种健康益处，美国儿科学会和世界卫生组织建议在出生后的前6个月完全母乳喂养。本研究旨在评价阿替洛尔在产后2-4周、3-4个月和6-8个月服用阿替洛尔治疗并喂养婴儿的妇女血浆、尿液和母乳中的药代动力学。